Time to resolve TA-TMA biomarkers after start of eculizumab therapy
| TA-TMA biomarker . | Number of days to resolve in responding patients, median (IQR) . | ||
|---|---|---|---|
| All participants . | Without bleeding . | With bleeding∗ . | |
| LDH returned to normal for age | 70 (33 -110) | 31 (7-44) | 154 (125-171) |
| Schistocytes absent for >14 d | 68 (40 -108) | 46 (38-114) | 76 (58-83) |
| No RBC transfusions for >14 d | 45 (19 - 76) | 40 (12-62) | 41 (20-80) |
| No platelet transfusions for >14 d | 60 (30 - 89) | 40 (28-64) | 78 (60-92) |
| Severe hypertension resolution | 69 (45 -117) | 79 (54-143) | 36 (26-69) |
| rUPCRof <1 mg/mg | 81 (45 -120) | 48 (14-81) | 110 (96-125) |
| sC5b-9 of <244 ng/mL | 5 (3 - 30) | 5 (2-29) | 8 (3-35) |
| All TA-TMA biomarkers (in days) | 156 (90-167) | 105 (81-162) | 158 (154-169) |
| All TA-TMA biomarkers (in weeks) | 22 (13-24) | 15 ( 12-23) | 23 (22-24) |
| TA-TMA biomarker . | Number of days to resolve in responding patients, median (IQR) . | ||
|---|---|---|---|
| All participants . | Without bleeding . | With bleeding∗ . | |
| LDH returned to normal for age | 70 (33 -110) | 31 (7-44) | 154 (125-171) |
| Schistocytes absent for >14 d | 68 (40 -108) | 46 (38-114) | 76 (58-83) |
| No RBC transfusions for >14 d | 45 (19 - 76) | 40 (12-62) | 41 (20-80) |
| No platelet transfusions for >14 d | 60 (30 - 89) | 40 (28-64) | 78 (60-92) |
| Severe hypertension resolution | 69 (45 -117) | 79 (54-143) | 36 (26-69) |
| rUPCRof <1 mg/mg | 81 (45 -120) | 48 (14-81) | 110 (96-125) |
| sC5b-9 of <244 ng/mL | 5 (3 - 30) | 5 (2-29) | 8 (3-35) |
| All TA-TMA biomarkers (in days) | 156 (90-167) | 105 (81-162) | 158 (154-169) |
| All TA-TMA biomarkers (in weeks) | 22 (13-24) | 15 ( 12-23) | 23 (22-24) |
Patients with clinically significant GI bleeding.